COO subtyping was previously demonstrated to be clinically relevant in this series,7 and the frequency of HLA-DRA expression was significantly lower in non-GCB DLBCL subtyped using either the Hans,43 Choi44 or Visco–Young45 IHC algorithms (all P<0.01; Figure 5b). Here, HLA-DRA is linked to diffuse large B-cell lymphoma.